Ainhoa Gonzalez-Pujana

Dr. Ainhoa Gonzalez-Pujana

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EMElena Munoz-Perez
Elena Munoz-Perez
AGAinhoa Gonzalez-Pujana
Ainhoa Gonzalez-Pujana
MIManoli Igartua
Manoli Igartua
EVEDORTA SANTOS VIZCAINO
EDORTA SANTOS VIZCAINO
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez
Considering the high prevalence and the complex pharmacological management of immune-mediated inflammatory diseases (IMIDs), the search for new therapeutic approaches for their treatment is vital. Although the immunomodulatory and anti-inflammatory effects of mesenchymal stromal cells (MSCs) have been extensively studied as a potential therapy in this field, direct MSC implantation presents some limitations that could slow down the clinical translation. Since the beneficial effects of MSCs have been mainly attributed to their ability to secrete a plethora of bioactive factors, their secretome has been proposed as a new and promising pathway for the treatment of IMIDs. Formed from soluble factors and extracellular vesicles (EVs), the MSC-derived secretome has been proven to elicit immunomodulatory effects that control the inflammatory processes that occur in IMIDs. This article aims to review the available knowledge on the MSC secretome, evaluating the advances in this field in terms of its composition, production and application, as well as analyzing the pending challenges in the field. Moreover, the latest research involving secretome administration in IMIDs is discussed to provide an updated state-of-the-art for this field. Finally, novel secretome delivery alternatives are reviewed, paying special attention to hydrogel encapsulation as one of the most convenient and promising strategies.

30 July 2020 in Biomaterials
Verified
Journal Article
Closed access
AGAinhoa Gonzalez-Pujana
Ainhoa Gonzalez-Pujana
KVKyle H. Vining
Kyle H. Vining
DZDavid K.Y. Zhang
David K.Y. Zhang
EVEDORTA SANTOS VIZCAINO
EDORTA SANTOS VIZCAINO
MIManoli Igartua
Manoli Igartua
DMDavid J. Mooney
David J. Mooney

1 December 2017 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AGAinhoa Gonzalez-Pujana
Ainhoa Gonzalez-Pujana
EVEDORTA SANTOS VIZCAINO
EDORTA SANTOS VIZCAINO
GOGorka Orive
Gorka Orive
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez

19 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AGAinhoa Gonzalez-Pujana
Ainhoa Gonzalez-Pujana
Teresa CarranzaTeresa Carranza
Teresa Carranza
EVEDORTA SANTOS VIZCAINO
EDORTA SANTOS VIZCAINO
MIManoli Igartua
Manoli Igartua
Pedro GuerreroPedro Guerrero
Pedro Guerrero
Koro de la CabaKoro de la Caba
Koro de la Caba
Complex scaffolds composed of micro- and nano-structures are a key target in tissue engineering and the combination of sequential 3D printing and electrospinning enables the fabrication of these multi-scale structures. In this work, dual 3D printed and electrospun polycaprolactone (PCL) scaffolds with multiple mesh layers were successfully prepared. The scaffold macro- and micro-porosity were assessed by optical and scanning electron microscopy, showing that electrospun fibers formed aligned meshes within the pores of the scaffold. Consequently, the hydrophilicity of the scaffold increased with time, enhancing cell adhesion and growth. Additionally, compression tests in back and forth cycles demonstrated a good shape recovery behavior of the scaffolds. Biological results indicated that hybrid PCL scaffolds are biocompatible and enable a correct cell culture over time. Moreover, MC3T3-E1 preosteoblast culture on the scaffolds promoted the mineralization, increased the alkaline phosphatase (ALP) activity and upregulated the expression of early and late osteogenic markers, namely ALP and osteopontin (OPN), respectively. These results demonstrate that the sequential combination of 3D printing and electrospinning provides a facile method of incorporating fibers within a 3D printed scaffold, becoming a promising approach towards multi-scale hierarchical scaffolds capable of guiding the osteogenic differentiation.

16 January 2020 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
AGAinhoa Gonzalez-Pujana
Ainhoa Gonzalez-Pujana
MIManoli Igartua
Manoli Igartua
EVEDORTA SANTOS VIZCAINO
EDORTA SANTOS VIZCAINO
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez
Introduction: Mesenchymal stromal cells (MSCs) present unique immunomodulatory properties that make them promising candidates for the treatment of inflammatory and immune disorders. MSC-mediated immunomodulation is a complex combination of mechanisms, in which the secretome plays a fundamental role. The plethora of bioactive molecules MSCs produce, such as indoleamine 2,3-dioxygenase (IDO) or prostaglandin E2 (PGE2), efficiently regulates innate and adaptive immunity. As a result, MSCs have been extensively employed in preclinical studies, leading to the conduction of multiple clinical trials. Areas covered: This review summarizes the effects of some of the key biomolecules in the MSCs secretome and the advances in preclinical studies exploring the treatment of disorders including graft-versus-host disease (GvHD) or inflammatory bowel disease (IBD). Further, late-stage clinical trials and the first MSC-based therapies that recently obtained regulatory approval are discussed. Expert opinion: Extensive research supports the potential of MSC-based immunomodulatory therapies. However, to establish the bases for clinical translation, the future of study lies in the standardization of protocols and in the development of strategies that boost the therapeutic properties of MSCs.

22 January 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
AGAinhoa Gonzalez-Pujana
Ainhoa Gonzalez-Pujana
AGAna Beloqui García
Ana Beloqui García
JAJosé Javier Aguirre
José Javier Aguirre
MIManoli Igartua
Manoli Igartua
EVEDORTA SANTOS VIZCAINO
EDORTA SANTOS VIZCAINO
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez
The ability of mesenchymal stromal cells (MSCs) to release a plethora of immunomodulatory factors makes them valuable candidates to overcome inflammatory bowel diseases (IBD). However, this cell therapy approach is still limited by major issues derived from nude MSC-administration, including a rapid loss of their immunomodulatory phenotype that impairs factor secretion, low persistence and impossibility to retrieve the cells in case of adverse effects. Here, we designed a licensing hydrogel system to address these limitations and thus, obtain a continuous delivery of bioactive factors. IFNγ-loaded heparin-coated beads were included in injectable in situ crosslinking alginate hydrogels, providing a 3D microenvironment that ensured continuous inflammatory licensing, cell persistence and implant retrievability. Licensing-hydrogel encapsulated human MSCs (hMSCs) were subcutaneously xenotransplanted in an acute mouse model of ulcerative colitis. Results showed that encapsulated hMSCs exerted a delocalized systemic protection, not presenting significant differences to healthy mice in the disease activity index, colon weight/length ratio and histological score. At day 7, cells were easily retrieved and ex vivo assays showed fully viable hMSCs that retained an immunomodulatory phenotype, as they continued secreting factors including PGE2 and Gal-9. Our data demonstrate the capacity of licensing hydrogel-encapsulated hMSCs to limit the in vivo progression of IBD.